Original articleLow-Fluence Photodynamic Therapy versus Ranibizumab for Chronic Central Serous Chorioretinopathy: One-Year Results of a Randomized Trial
Section snippets
Methods
This prospective, single-center, randomized, parallel-arm, 1-year, controlled clinical trial of the patients with chronic CSC was prospectively approved by the Institutional Review Board and Ethics Committee at Seoul National University Hospital and the Korean Food and Drug Administration. The study was conducted in accordance with the tenets of the Declaration of Helsinki. Written, informed consent was obtained from each participant before enrollment. This study was registered at //clinicaltrial.gov
Results
Thirty-four eyes from 32 patients with chronic CSC were enrolled, of which 18 eyes (52.9%) were randomly placed into the low-fluence PDT group and 16 eyes (47.1%) into the ranibizumab group. All 18 eyes in the low-fluence PDT group completed the 12 months of follow-up. In the ranibizumab group, 2 patients were lost to follow-up at months 4 and 8 owing to refusal of rescue treatment. The mean age of the patients was 50.8±7.7 years (range, 35–65 years), with 26 male (81.3%) and 6 female (18.8%)
Discussion
This clinical trial compared treatment outcomes between low-fluence PDT and intravitreal ranibizumab in patients with chronic CSC. This study demonstrates the overall superiority of low-fluence PDT compared with intravitreal ranibizumab in terms of efficacy outcomes.
Regarding anatomic outcomes, a significantly greater proportion of subjects in the low-fluence PDT group (88.9%) maintained complete resolution of the SRF without rescue treatment compared with the ranibizumab group (12.5%). The
References (30)
- et al.
Choroidal capillary and venous congestion in central serous chorioretinopathy
Am J Ophthalmol
(1996) - et al.
Chronic central serous chorioretinopathy: photodynamic therapy
Am J Ophthalmol
(2004) - et al.
Transient reduction in retinal function revealed by multifocal electroretinogram after photodynamic therapy
Am J Ophthalmol
(2004) - et al.
Half-dose verteporfin photodynamic therapy for acute central serous chorioretinopathy: one-year results of a randomized controlled trial
Ophthalmology
(2008) - et al.
Diffuse retinal pigment epitheliopathy complicating systemic corticosteroid treatment
Br J Ophthalmol
(1995) Pathogenesis of disciform detachment of the neuroepithelium
Am J Ophthalmol
(1967)- et al.
Indocyanine green angiography of central serous chorioretinopathy
Int Ophthalmol
(1986) - et al.
Digital indocyanine green videoangiography of central serous chorioretinopathy
Arch Ophthalmol
(1994) - et al.
Indocyanine green videoangiography of older patients with central serous chorioretinopathy
Retina
(1996) - et al.
Persistent and bilateral choroidal vascular abnormalities in central serous chorioretinopathy
Retina
(1999)
Choroidal findings in the course of idiopathic serous pigment epithelium detachment detected by indocyanine green videoangiography
Retina
Choroidal vascular remodelling in central serous chorioretinopathy after indocyanine green guided photodynamic therapy with verteporfin: a novel treatment at the primary disease level
Br J Ophthalmol
Photodynamic therapy for chronic central serous chorioretinopathy
Retina
Dose-related structural effects of photodynamic therapy on choroidal and retinal structures of human eyes
Graefes Arch Clin Exp Ophthalmol
Ocular changes after photodynamic therapy
Invest Ophthalmol Vis Sci
Cited by (64)
Characteristics Related to Visual Acuity Loss After Successful Photodynamic Therapy for Eyes With Central Serous Chorioretinopathy
2023, American Journal of OphthalmologyA Photodynamic Therapy Index for Central Serous Chorioretinopathy to Predict Visual Prognosis Using Pretreatment Factors
2023, American Journal of OphthalmologyFuji sign: Prevalence and predictive power to photodynamic therapy in chronic central serous chorioretinopathy
2023, Photodiagnosis and Photodynamic TherapyEvaluation of clinical and functional sequels of central serous chorioretinopathy. A case series analysis
2022, Archivos de la Sociedad Espanola de OftalmologiaVenous overload choroidopathy: A hypothetical framework for central serous chorioretinopathy and allied disorders
2022, Progress in Retinal and Eye ResearchCitation Excerpt :Randomized controlled studies of varying sizes found patients receiving PDT did better than those getting a placebo (Chan et al., 2008; Wu et al., 2011). The trials comparing PDT to anti-vascular endothelial growth factors were underpowered and no conclusions could be made about relative efficacy (Bae et al., 2014; Semeraro et al., 2012). PDT was compared to micro-pulse laser in two trials, both showing improved efficacy with PDT (Kretz et al., 2015; van Dijk et al., 2018).
Financial support: Novartis Korea, Seoul, Korea.
The sponsor or funding organization had no role in the design or conduct of this research. No conflicting relationship exists for any author.